Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 4, 2011, Pages 373-377

  Ozturk, Banu Turgut ^a   Kerimoglu, Hurkan ^a   Bozkurt, Banu ^a   Okudan, Suleyman ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL SUBFIELD MACULAR THICKNESS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DRUG EFFICACY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT DURATION; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79961200418     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2010.0195     Document Type: Article

References (22)

1. Klein, R., Klein, B.E., and Moss, S.E. Visual impairment in diabetes. Ophthalmology 91:1-9, 1984. (Pubitemid 14184710)
2. Qaum, T., Xu, Q., Joussen, A.M., Clemens, M.W., Qin, W., Miyamoto, K., Hassessian, H., Wiegand, S.J., Rudge, J., Yancopoulos, G.D., and Adamis, A.P. VEGF-initiated bloodretinal barrier breakdown in early diabetes. Invest. Ophthalmol. Vis. Sci. 42:2408-2413, 2001. (Pubitemid 32848873)
3. Khurana, R.N., Do, D.V., and Nguyen, Q.D. Anti-VEGF Therapeutic Approaches for Diabetic Macular Edema. Int. Ophthalmol. Clin. 49:109-119, 2009.
4. ETDRS Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 94:761-774, 1987.
5. Heiduschka, P., Fietz, H., Hofmeister, S., Schultheiss, S., Mack, A.F., Peters, S., Ziemssen, F., Niggemann, B., and Julien, S., The Tübingen Bevacizumab Study Group: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest. Ophthalmol. Vis. Sci. 48:2814-2823, 2007. (Pubitemid 351261238)
6. Fang, X., Sakaguchi, H., Gomi, F., Oshima, Y., Sawa, M., Tsujikawa, M., Ikuno, Y., Kamei, M., Kusaka, S., and Tano, Y. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular edema. Acta Ophthalmol. 86:800-805, 2008.
7. Algvere, P.V., Steen, B., Seregard, S., and Kvanta, A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol. 86:482-489, 2008.
8. Mordenti, J., Cuthbertson, R.A., Ferrara, N., Thomsen, K., Berleau, L., Licko, V., Allen, P.C., Valverde, C.R., Meng, Y.G., Fei, D.T., Fourre, K.M., and Ryan, A.M. Comparison of the intraocular tissue distribution, pharmacokinetics and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol. Pathol. 27:536-544, 1999. (Pubitemid 29446822)
9. Querques, G., Bux, A.V., Martinelli, D., Iaculli, C., Del Curatolo, M.V., and Noci, N.D. Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection. Retina 29:1274-1281, 2009.
10. Chun, D.W., Heier, J.S., Topping, T.M., Duker, J.S., and Bankert, J.M. A pilot study of multiple intravitreal injection of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113:1706-1712, 2006. (Pubitemid 44442451)
11. Browning, D.J., Glassman, A.R., Aiello, L.P., Bressler, N.M., Bressler, S.B., Danis, R.P., Davis, M.D., Ferris, F.L., Huang, S.S., Kaiser, P.K., Kollman, C., Sadda, S., Scott, I.U., and Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology 115:1366-1371, 2008.
12. Ferrara, N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr. Rev. 25:581-611, 2008.
13. Vinores, S.A., Youssri, A.I., Luna, J.D., Chen, Y.S., Bhargave, S., Vinores, M.A., Schoenfeld, C.L., Peng, B., Chan, C.C., Larochelle, W., Green, W.R., and Campochiaro, P.A. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol. Histopathol. 12:99-109, 1997. (Pubitemid 27106924)
14. Adamis, A.P., Miller, J.W., Bernal, M.T., D'Amico, D.J., Folkman, J., Yeo, T.K., and Yeo, K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118: 445-450, 1994. (Pubitemid 24307211)
15. Funatsu, H., Yamashita, H., Ikeda, T., Nakanishi, Y., Kitano, S., and Hori, S. Angiotensin II and vascular endothelial growth factor in the vitreous humor of diabetics with macular edema and other retinal disorders. Am. J. Ophthalmol. 133:537-543, 2002. (Pubitemid 34258063)
16. Roh, M.I., Byeon, S.H., and Kwon, O.W. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina 28:1314-1318, 2008.
17. Ferrara, N., Hillan, K.J., Gerber, H.P., and Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3:391-400, 2004. (Pubitemid 38618122)
18. Seo, J.W., and Park, I.W. Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J. Ophthalmol. 23:17-22, 2009.
19. Arevalo, J.F., Sanchez, J.G., Wu, L., Maia, M., Alezzandrini, A.A., Brito, M., Bonafonte, S., Lujan, S., Diaz-Llopis, M., Restrepo, N., Rodriguez, F.J., and Udaondo-Mirete P; Pan- American Collaborative Retina Study Group. Primary intravitreal bevacizumab for diffuse diabetic macular edema: The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 116:1488-1497, 2009.
20. Kook, D., Wolf, A., Kreutzer, T., Neubauer, A., Strauss, R., Ulbig, M., Kampik, A., and Haritoglou, C. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina 28:1053-1060, 2008.
21. Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G.E., Massin, P., Schlingemann, R.O., Sutter, F., Simader, C., Burian, G., Gerstner, O., and Weichselberger, A; RESTORE study group. The RESTORE Study Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema. Ophthalmology 118:615-625, 2011.
22. Shahar, J., Avery, R.L., Heilweil, G., Barak, A., Zemel, E., Lewis, G.P., Johnson, P.T., Fisher, S.K., Perlman, I., and Lowenstein, A. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262-269, 2006. (Pubitemid 44318177)